DICE Therapeutics (DICE Therapeutics) Momentum Rank : 0 (As of May. 24, 2024)

View and export this data going back to 2021. Start your Free Trial

What is DICE Therapeutics Momentum Rank?

DICE Therapeutics has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

DICE Therapeutics Momentum Rank Related Terms

Thank you for viewing the detailed overview of DICE Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

DICE Therapeutics (DICE Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DICE Therapeutics Inc (NAS:DICE) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 East Jamie Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.dicetherapeutics.com

DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.

Executives

Northpond Ventures Gp, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
John R. Jacobsen	officer: CSO	C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Scott M. Robertson	officer: CFO & CBO	C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Lu Timothy	officer: CMO	C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Kevin Judice	director, officer: CEO	6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
James Paul Scopa	director	601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Lisa Bowers	director	C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Mittie Doyle	director	C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Michael P. Rubin	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Shaan-chirag C Gandhi	director	NORTHPOND VENTURES, 7500 OLD GEORGETOWN ROAD, BETHESDA MD 20814
Northpond Ventures Ii, Lp	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Stephen Zachary	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902